Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery

This study will evaluate the benefits of continuing celecoxib through six weeks of total knee arthroplasty recovery. This is a randomized, double blind study with a group of approximately 130 primary total knee patients. All patients will receive celecoxib throughout their hospitalization as per current minimally invasive total knee arthroplasty protocol. At the time of hospital discharge, participating patients will be randomly placed on either celecoxib 200mg twice a day or a placebo twice a day.

This study will determine if the continued use of celecoxib for six weeks after total knee arthroplasty hospitalization will further decrease narcotic consumption, improve knee range of motion, improve ambulatory ability, and improve patient satisfaction over patients receiving celecoxib only during the acute hospitalization.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Management Agnosia Celecoxib Function Minimally Invasive Total Knee Arthroplasty Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pathological Conditions, Signs and Symptoms Perceptual Disorders Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

DePaul Health Center

St Louis, Missouri, 63044, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

having undergone a minimally invasive total knee by select surgeon
voluntarily enrolled
independent community ambulators
only patients being discharged directly home

Exclusion criteria

celecoxib allergy or intolerence
Renal insufficiency (defined as serum creatine level >1.5 mg/dL or BUN level >22mg/dL
History of bleeding gastic or duodenal ulceration
New York Heart Association Class III or IV Congestive Heart Failure
Previous myocardial infarction or cerebralvascular event
Severe inflammatory bowel disease
Known coagulation abnormality or hepatic disease
Chronic coumadin administration
Refusal by primary or cardiac physician

Treatment and study plan

Celecoxib

Drug

Sponsors and collaborators

Lead sponsor

St. Louis Joint Replacement Institute

Other

Collaborators

Pfizer
Zimmer Biomet

Registry information

Official study title

Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery: A Randomized Controlled Study

Important dates

Study start: 2007
Primary completion: 2009
Study completion: 2009
First posted: May 17, 2007
Registry last updated: Apr 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed